NeuroMetrix, Inc. (NASDAQ:NURO) reported today that Notices of Allowance has been issued for patents covering key technological features of the Company’s Quell(R) Wearable Pain Relief Technology(TM) by the European Patent Office, the Japan Patent Office, and the State Intellectual Property Office of the People’s Republic of China.
At the end of the most recent quarter, NeuroMetrix Inc. (NASDAQ:NURO)’s balance sheet showed total assets worth $11.09M. Compared to the past period, the newly reported debt increased/decreased by falling.
NeuroMetrix Inc.’s total liabilities exiting the latest quarter stood at $3.24M.
Recently, NeuroMetrix, Inc. (NASDAQ:NURO) announced that
Let?s look into the technical of the stock
The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.
The assets that the company listed at the end of the most recent quarter included cash balance of 6.9M%. Net operating cash from the latest quarter was $(3.35M), leading to free cash flow of $(3.35M). Compared to the past period, net change in case came to $2.95M.
The cash that NeuroMetrix Inc. generated in the latest quarter stemmed from sales of 4.31M%, which increased 0.47% from a year-ago period.
It cost NeuroMetrix Inc. some $2.7M to generate the sales of 4.31M% reported in the latest quarter, with that being the cost of sales. After factoring in the cost of sales in the income calculations, NeuroMetrix Inc. emerged with gross income of $1.61M.
After also taking into account other operating expenses, the company ended up with a net income figure that when it divided with the number of outstanding shares it ended up with EPS (earnings per share) of $(0.91). For perspective on how NeuroMetrix Inc. arrived at the EPS figure, investors should know that the company finished the latest quarter with diluted outstanding shares of 8.01M.
What?s in the offing in terms of EPS for the next quarter? Wall Street analysts on the average say investors should expect from NeuroMetrix Inc. EPS of $ in the next quarter.
In addition to predicting the next quarter’s EPS, analysts have also weighed in on the stock of NeuroMetrix Inc. regarding whether investors should view it as a BUY, SELL or HOLD.’